While a surge in patient reporting of levothyroxine and the hormonal intrauterine device (Mirena®) due to a larger media coverage in France has been previously highlighted [ 13 , 36 ], our results show that independent to these “reporting surges,” an increasing trend persisted over time.
← all excerpts
Patient involvement in pharmacovigilance: determinants and evolution of reporting from 2011 to 2020 in France.
1
—
—